Tier 1 — highest

N-Acetylcysteine for Cardiac Protection During Coronary Artery Reperfusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Sher Ali Khan, Ashley M Campbell, Yingying Lu, Lingling An, Joseph S Alpert, Qin M Chen
Front Cardiovasc Med 2021 8:752939

Bibliography

PubMed
PMID 34869660
PubMed Central
PMC8640098
DOI
10.3389/fcvm.2021.752939
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignSystematic review and meta-analysis of randomized controlled trials
ModelHuman
Sample28 RCTs; 2,174 participants
InterventionNAC around coronary reperfusion procedures
DurationPeriprocedural
EndpointsCardiac biomarkers; Atrial fibrillation; Left-ventricular function; Clinical events

What the study showed, in plain terms

Large pooled analysis of NAC as a cardioprotective adjunct during coronary reperfusion.

Key findings

Pooled results showed at most modest or nonsignificant signals across several cardiac outcomes rather than a clear clinical protection effect.

What this study can and cannot tell us

Substantial heterogeneity in route, dose, reperfusion setting and endpoints; not evidence for general cardiovascular supplementation.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology